



This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. 
It is posted here by agreement between Elsevier and the University of Turin. 
Changes resulting from the publishing process - such as editing, corrections, 
structural formatting, and other quality control mechanisms - may not be reflected in 
this version of the text. The definitive version of the text was subsequently 
published in  
 
Prev Vet Med. 2013 Nov 1;112(3-4):414-22. doi: 10.1016/j.prevetmed.2013.08.011. Epub 2013 
Sep 3. 
You may download, copy and otherwise use the AAM for non-commercial purposes 
provided that your license is limited by the following restrictions: 
 
(1) You may use this AAM for non-commercial purposes only under the terms of 
the CC-BY-NC-ND license.  
(2) The integrity of the work and identification of the author, copyright owner, and 
publisher must be preserved in any copy.  
(3) You must attribute this AAM in the following format: Creative Commons 
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en), 
[+ Digital Object Identifier link to the published journal article on Elsevier’s 













Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma 
after receiving surgery: An individual patient data meta-analysis 
A.F. Schmidtab'c, M. Nielenc, O.H. Klungelab, A.W. Hoesa, A. de Boerb, R.H.H. Groenwoldab, J. 
Kirpensteijnd, for the V.S.S.O. Investigators1 
a
 Julius Centerfor Health Sciences and Primary Care, University Medicai Center Utrecht, P.O. 
Box 85500,3508 GA Utrecht, The 
Netherlands 
b
 Division of Phannacoepidemiology and Clinical Phannacology, UtrechtInstitutefor 
Pharmaceuticai Sciences, P.O. Box 80082,3508 TB 
Utrecht, The Netherlands 
c
 Department of Farm Animai Health, Faculty of Veterinary Medicine, Utrecht University, 
Yalelaan 7, Utrecht 3584 CI, The Netherlands 
d
 Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, 
Utrecht University, Yalelaan 8, Utrecht 3584 
CM, The Netherlands 
1 See acknowledgements for individual members and their affiliation. 
Abstract 
Recently an aggregated data meta-analysis showed that serum alkaline phosphatase (SALP) and 
proximal humerus location are predictors for shorter survival in canine osteosarcoma. To identify 
additional prognostic factors of mortality and metastasis an individual patient data meta-analysis 
(IPDMA) was conducted. Individual patient data from 20 studies, identified via the VSSO society, 
were pooled. Univariable and multivariable hazard ratios (HR) for metastasis and mortality were 
assessed, using stratified Cox models. The study included 1405 dogs who received surgical treatment, 
of which thè metastasis status was measured in 1155 dogs and mortality status in 1336 dogs ; median 
survival was 256 days. High versus normal SALP and weight (kg) were associated with an increase in 
hazard of metastasis [HR 1.34 (95%CI 1.07; 1.68) and HR 1.02 (per kg increase) (95%CI 1.01 ; 1.03)] 
and for mortality [HR 1.43 (95%CI 1.16; 1.77) and HR 1.02 (95%CI 1.01 ; 1.02)]. Distal radius tumor was 
associated with a lower hazard of metastasis compared to other locations: HR 0.75 (95%CI 0.58; 0.96). 
Proximal humerus and distal femur or proximal tibia location were related with an increased mortality: 
HR 1.53 (95%CI 1.26; 1.84) and HR 1.23 (95%CI 1.01 ; 1.49) compared to other locations. Older age 
(years) was associated with a higher hazard for mortality [HR 1.06 per year (95%CI 1.03 ; 1.09) ] but not 
for metastasis: HR 1.03 (95%CI 0.99 ; 1.06). These results confirm findings from a recent aggregated data 
meta-analysis and (in addition) showed that tumor location, SALP, weight were prognostic factors for 
both mortality and metastasis. Age was a prognostic factor for mortality but not for metastasis. 
 
1. Introduction 
Osteosarcoma (OS) is a malignant tumor of mesenchymal origin that produces osteoid. Similarities 
between human and canine OS are striking and include thè bimodal age distribution, the high incidence 
of morbidity and mortality, the site of the tumor, histologic features and the response to the various 
treatment modalities (Withrow and Wilkins, 2010; Rowell et al., 2011). The biggest difference is that 
OS is much more common in dogs than in people. The majority of canine primary bone tumors can be 
classified as OS, which predominantly occurs in large and giant breeds (Norrdin et al., 1989; Spodnick 
et al., 1992; Cooley and Waters, 1997; Ru et al., 1998; McNeill et al., 2007). OS dogs, treated only by 
amputation, have a median survival time of five months or less, with the majority succumbing to 
metastatic disease (Brodey and Abt, 1976; Straw et al., 1991; Spodnick et al., 1992). Due to advances 
in disease management overall survival can be extended to 1 year (Straw et al., 1991). Given the 
increased treatment options, such as adjuvant chemotherapy, 'limb-sparing' surgery and radio-ablative 
methods, it has become even more important to differentiate between dogs with a worse and relatively 
improved prognosis. Numerous studies have explored the prognostic value of, for example gender, 
neuter status, age or serum alkaline phosphatase (SALP), but these studies have important limitations. 
Most notably, the relatively small number of patients included in these studies precludes precise 
estimation of the prognostic consequences of these factors. A possible solution for this is collecting and 
pooling reported prognostic associations from individual studies. Recently, Boerman et al. (2012) 
conducted an aggregated data meta-analysis. This meta-analysis showed that elevated SALP and 
location of OS in the (proximal) humerus are associated with a shorter disease free survival time. 
However, as Boerman acknowledges, the included studies did not analyze SALP and tumor location 
consistently; some explored the univariable association, while other used multivariable methods. 
Furthermore, other characteristics, for example age, weight and neuter status, could not be analyzed 
because these were not reported by a sufficient number of studies. 
An alternative to pooling the aggregated data is to acquire the individual patient data files. An 
individual patient data meta-analysis (IPDMA) permits for more uniform analyses with regard to 
follow-up time, categorization of variables, missing values and analysis methods used (Stewart and 
Parmar, 1993; Riley et al., 2010). Furthermore, individual patient data allows exploring associations not 
reported in the original publications. Consequently, such prognostic IPDMAs are powerful tools to 
identify prognostic factors and subgroups of patients with different prognoses. We conducted an 
IPDMA in order to estimate the independent prognostic value of gender, neuter status, age, weight, 
breed, tumor location and SALP in predicting mortality or metastasis in canine OS.
2. Methods 
2.1. Inclusion of individual patient data and assessment of data quality 
To explore the relations between patient characteristic and (DF) survival we identified studies via 
the Veterinary Society of Surgical Oncology (VSSO). In January 2012 a call for collaboration was send 
out to VSSO members and other veterinary researchers. We attempted to include data from as many 
different researchers and institutes as possible. No a priori sample size calculations were performed. 
Data were deemed eligible if baseline patient characteristics of OS dogs and time to event (death or 
metastasis) were recorded. To reduce the possibility of publication bias (Easterbrook et al., 1991), 
published and unpublished studies were both eligible. Impossible or unlikely data entries were explored 
and remaining irregularities were discussed with the original investigators. Data were collected on 
gender, neuter status, age (years), weight (kg), breed (Rottweiler, Golden Retriever, Labrador Retriever, 
Greyhound, Doberman, Irish Setter, mixed breeds, and other breeds), tumor location (proximal 
humerus, distal femur or proximal tibia, distal radius, and other locations), dichotomous SALP (using 
study specific cut-off values for high and normal SALP levels), surgery (limb-sparing, amputations), 
chemotherapy (no chemotherapy, cisplatin, lobaplatin or carboplatin, doxorubicin, doxorubicin 
combinations), and other treatments. To prevent low cell counts we refrained from using finer 
categories for breed, tumor location and chemotherapy. SALP status (at baseline) was dichotomized to 
follow clinical practice and because continuous SALP showed a positive linear sloped relationship 
with the outcomes that stabilized to a flat slope at high SALP values. Patients who did not receive 
surgery, mostly due to euthanasia (n = 197), who received an infrequently used chemotherapeutic 
protocol (n = 13), or who received radiation therapy (n = 11) were excluded from all analyses. 
2.2. Data analysis 
To illustrate how patient characteristics were related to mortality or metastases at the clinically 
relevant time points of 5 and 12 months (Brodey and Abt, 1976; Straw et al., 1991; Spodnick et al., 
1992), we stratified baseline characteristics according to the outcome status (mortality and metastasis) 
at these points. Univariable associations were estimated using a stratified Cox proportional hazards 
model (Harrell, 2001). All the models were stratified by study to account for possible differences in 
baseline hazard. If a variable was missing for a certain patient, that patient was excluded from the 
univariable analysis (i.e., listwise deletion). 
We then performed a multivariable Cox proportional hazards analysis (stratified by study) to assess the 
independent associations between prognostic factors and outcome. Subjects were censored if they were 
lost to follow-up or died (censoring for mortality was only applied in models using the metastasis 
outcome). Associations are given as hazard ratios (HRs) with 95% confidence intervals (95%CI) and 
p-values using an alpha of 0.05. For categorical variables a p-value for trend was computed and the 
individual associations were only explored if this overall test was significant (i.e., p<0.05). All 
multivariable models were corrected for chemotherapy status. Variable selection for the multivariable 
model was based on prior knowledge, no data driven selection method was used (i.e., stepwise 
selection). The proportional hazard (PH) assumption of the Cox models was checked based on 
Schoenfield residuals (Harrell, 2001). For the continuous variables weight and age linearity with the 
outcome was assessed using restricted cubic splines plots (Harrell et al., 1996); relations appeared to 
be linear. To determine how well the multivariate models discriminate between subjects with a 
short time to event and subjects with a longer time to event, the c-statistic (i.e., area under the 
receiver operator characteristic curve) was calculated (Steyerberg et al., 2010). The c-statistic 
represents the proportion of pairs of subjects where the subject with the longest observed time 
to event also received the longest predicted time to event; the c-statistic varies from 0.5 (no 
discrimination) and 1 (perfect discrimination). 
In the multivariable analysis missing values were imputed, across studies, based on the 
areglmputation algorithm with ten imputations (Sterne et al., 2009; Harrell, 2012a). In each of 
the ten imputed datasets, a multivariable Cox proportional hazards analyses was conducted and 
results were pooled using Rubin's rule (Marshall et al., 2009). The study by Sottnik et al. 
(2010) (n = 69) did not provide information on time until death. Similarly, studies by Phillips et 
al. (2009) (n = 156) and Berg et al. (1997) (n = 94) did not record information on time to 
metastasis. These studies were only used for the analyses they provided data for.
2.3. Sensitivity analysis 
Effect estimates of the association between prognostic factors and non-mortality outcomes, 
such as metastasis, are potentially biased by competing risks. (Lau et al., 2009). In the case of 
time till metastasis a subject can be censored due to competing risks such as death 
(informative censoring). In such a case it is obviously wrong to assume that the subjects will 
get the event somewhere in the future (which is traditionally assumed when censoring). If 
this informative censoring is systematically related to a specific group (e.g., high SALP) 
censoring the deceased subjects inflates the cumulative incidence and competing risk occurs. 
Instead of censoring subjects who die before developing a metastasis a competing risk analysis 
keeps these subjects in the denominator, decreasing the cumulative incidence. In canine OS, 
most subjects first experience a metastasis before dying, therefore the impact of competing risk 
by death is expected to be small. Nevertheless we conducted competing risk analyses to assess 
how much this impacted our results (Satagopan et al., 2004). We also assessed the impact of 
missing observations through a sensitivity analysis in which a multivariate analysis was 
conducted using only those subjects with completely observed data. Additionally, to determine 
whether including subjects from small studies or unpublished studies biased our results we 
performed all analyses separately for large (50 or more subjects) and small studies (less than 50 
subjects) and also stratified for publication status (i.e., if the study was published or not). To 
determine how influential the inclusion was of subjects who were not treated with 
chemotherapy, all analyses were also performed after excluding these patients. Finally, we 
assessed the impact of grouping lobaplatin and carboplatin in one group by repeated the 
analyses using separate categories for these chemotherapies. 
All analyses were carried out with the R statistical package version 3.0.0 (R Development 
Core Team, 2013), the survival (Therneau, 2012), the rms (Harrell, 2012b) and the Hmisc 
(Harrell, 2012a) packages. 
 
3. Results 
Data from 20 studies were included in this IPDMA, of which 11 studies were previously 
published (Kurzman et al., 1995; Berg et al., 1997; Kirpensteijn et al., 2002; Vail et al., 2002; 
Morello et al., 2003; Moore et al., 2007; Bacon et al., 2008; Kow et al., 2008; Phillips et al., 
2009; Sottnik et al., 2010). 19 studies reported solely on large breed dogs, while the unpublished 
study of Dr. Amsellem included 36 small breed canines. Characteristics of these studies are 
presented in Table 1. Eighteen studies (1155 patients) provided data on metastasis status and 
nineteen studies (1336 patients) provided information on mortality. 
3.2. Univariable analysis 
At 5 months, in the 550 dogs without missing data, 153 dogs developed a metastasis (Table 
2). High weight (per kg) was related to an increase in metastasis hazard: hazard ratio (HR) 1.02 
(95%CI 1.00; 1.03). Compared to the category other tumor locations, the distal radius category 
was associated with a decrease in hazard: HR 0.40 (95%CI 0.23; 0.68). Elevated baseline SALP 
was associated with an increased hazard of metastasis: HR2.12 (95%CI 1.52; 2.95); see Appendix 
I Figure Al for the Kaplan-Meier curves of SALP. Using other breeds as a reference Doberman 
subjects were related to a higher hazard, while mixed breed subjects were associated with a 
lower hazard: [HR2.16 (95%CI 1.06; 4.42) and HR 0.49 (95%CI 0.29; 0.84)]. By 1 year of 
follow-up the associations for metastasis of OS were similar to the results at 5 months (Table 2); 
median DF survival was 234 days. 
The median survival was 256 days, based on the 598 dogs that had no missing data. At 5 
months of follow up, the factors tumor location, breed and SALP at baseline were both 
univariable related to mortality and the magnitudes of the observed relations were similar to 
those for metastasis. At 1 year, weight, location, breed and SALP showed similar and 
significant associations as found for metastasis at 1 year (Appendix I table Al). 
3.2. Multivariable analysis 
After imputing missing values, 1155 subjects were available for the metastasis outcome 
(Table 3). By the end of follow-up 765 experienced a metastasis. Weight was associated with an 
increased hazard [HR 1.02 (per kg increase) (95% CI 1.01; 1.03)], as well as high SALP [HR 1.34 
(95%CI 1.07; 1.68)]. Compared to other tumor locations, patients with a distal radius OS were 
associated with a decreased hazard of metastases: HR 0.75 (95%CI 0.58; 0.96). Furthermore, the 
proximal humerus location was associated with an increased hazard of metastases, however 
this association was not significant: HR 1.21 (95%CI 0.96; 1.53). Similarly, breed was no longer 
significantly associated with metastasis after adjusting for other baseline characteristics. 
For the outcome mortality, 1336 dogs were available for analysis, of which 1076 died. The 
associations between weight and mortality, and SALP and mortality were similar to those found 
for the outcome metastasis (Table 3). Compared to the category other OS locations, proximal 
humerus tumors were associated with a higher hazard of mortality: HR 1.53 (95%CI 1.26; 
1.84). Similarly, having an OS at the distal femur or proximal tibia was related to an increased 
hazard: HR 1.23 (95%CI 1.01; 1.49). Finally, older aged subjects were also related to a higher 
hazard of mortality: HR 1.06 per year (95%CI 1.03; 1.09). 
The discriminative performance of the multivariable models was modest: the model for the 
outcome metastasis had a c-statistic of 0.63, whereas the model for the outcome mortality had a 
c-statistic of 0.61. 
 
3.3. Sensitivity analysis 
Fig. 1 shows the Kaplan-Meier survival curves for the outcome metastasis (with and 
without accounting for competing risks). Twenty nine (4%) subjects died without 
experiencing a metastasis event before dying. Consequently, ignoring competing risks had 
little impact on results: the standard Kaplan-Meier estimates only marginally overestimate the 
cumulative incidence of metastases when accounting for competing risks. 
Additional sensitivity analyses (on the impact of missing observations, size of the included 
studies, publication status of the included studies, and chemotherapy status of the dogs) did 
not show material difference compared to the results presented in Table 3. Results of these 
sensitivity analyses are available upon request. 
 
4. Discussion 
In our IPD meta-analysis on prognostic factors for metastasis and mortality among dogs with 
OS, weight, SALP and tumor location were independently prognostic predictors of mortality as 
well as metastasis. Age was significantly related with mortality only. 
In accordance with the "aggregated data" meta-analysis by Boerman et al. (2012), we found 
that elevated SALP was associated with a higher hazard of early mortality or metastasis. 
However, the Boerman study showed somewhat larger and less precise estimates [HR 1.62 
(95%CI 1.21; 2.17) for mortality and 1.96 (95%CI 1.50; 2.56) for metastasis] compared to our 
results: HR 1.43 (95%CI 1.16; 1.77) and HR 1.34 (95%CI 1.07; 1.68). Compared to other tumor 
sites, proximal humerus and distal femur or proximal tibia OS locations were related to an 
increased mortality hazard, but not metastasis. This is different from the Boerman study, which 
concluded that proximal humerus was significantly associated with both mortality and 
metastasis [HR 1.86 (95%CI 1.34; 2.57) and 2.53 (95%CI 1.34; 4.77)]. Furthermore, we found 
that having an OS tumor at the distal radius was associated with a decreased metastasis hazard. 
Our IPDMA also showed that independent of breed, high weight increased the hazard of both 
metastases and mortality. Possibly, this is due to the crude categorisation of the breed variable, with a 
large "other" category resulting in unexplained variance. Also different from the findings of the 
Boerman study was that we found age to be significantly related with mortality (increasing the 
hazard). 
In this section we will discuss the limitation and strengths of our study. First, the number of patients 
with at least one missing observation was high (52% for the metastasis outcome and 57% for 
mortality). This was predominantly driven by SALP, which was only measured in 9 out of 20 studies. 
In aggregated meta-analyses, like the one conducted by Boerman et al. (2012), it is difficult to deal 
with missing data. In the current study we used an IPDMA design, which allows for imputation of 
missing values. Like all studies with missing observations, it is possible that missingness was 
dependent not only on measured factors but also on unmeasured factors, thus results may still be 
biased even though missing data was multiple imputed. However, assuming that at least some of the 
missing values are dependent on measured factors, imputing missing values would likely decrease 
bias compared to a complete cases analysis. Second, several sensitivity analyses were performed, all 
showing similar associations as our main analysis, confirming the robustness of our findings. Third, 
most studies used 1 or 2 specific chemotherapy regimens, making it difficult to distinguish between 
chemotherapy effects and other study-specific influences. Thus, while it seems essential to include 
chemotherapy in modeling the independent prognostic associations between patient characteristics 
and outcomes, observed associations between chemotherapy and outcomes should not be interpreted 
causally. Fourth, none of the baseline variables, except chemotherapy (and only in some studies), were 
randomly allocated. Therefore, it is possible that unmeasured or residual confounding influence our 
results. Given that it is impossible to randomly allocate baseline characteristics such as gender or age, 
every study exploring these associations is potentially hampered by the possibility of confounding. 
Causal interpretation of observed associations might therefore lead to erroneous conclusions. For 
example, when, contrary to the association reported here, there is no causal relationship between 
weight and mortality (possible the reported association is due to some unmeasured protective genetic 
factor that is closely related to lower weight) intervening on weight will have no effect on the outcome. 
However, in such a situation (no causal relationship of weight) weight will still provide useful 
information on the baseline risk for the outcome. Thus, the importance of causality of the here 
reported associations depends on the goal; either to intervene on risk factors or to use those factors for 
prognostication. Fifth, meta-analyses can be subject to publication bias (i.e., bias due to including 
published studies only) (Easterbrook et al., 1991). By recruiting data via the VSSO network, about 40% 
of the included subjects were from unpublished sources, making the potential for publication bias 
smaller. On the other hand, some researchers did not respond to our requests for collaboration 
therefore results presented here do not include all possible data and we cannot rule out the possibility 
that inclusion of more data could change our estimations. Finally, the discriminative ability of all 
models was modest. Including clinical predictors like grade or type of tumor could potentially increase 
this discriminative ability. However, in the current study this was impossible due to the large number 
of studies that did not record data on these variables. 
Our present study used relatively new study techniques to combine individual patient data from 
different sources termed individual patient data meta-analysis (IPDMA). While an IPDMA requires 
big investments regarding time and resources we believe that the opportunities of using individual 
patient data compared to the alternative of relying on aggregated data outweigh this burden. An 
advantage of conducting an IPDMA is that one can explore relations not reported by the 
original authors. In our case this allowed us to estimate 7 associations while the Boerman 
aggregated data meta-analysis (Boerman et al., 2012) could only explore 3 associations. 
Similarly, IPMDA techniques ensure that when one wants to conduct multivariable analysis 
all estimates are corrected for the same set of variables. Without the same corrections, one has 
to rely on the reported estimates and as Boerman showed it is likely that every study uses 
distinct sets of covariables. A third advantage is that one can uniformly recode the data this 
can be particularly important if different cut off values or reference categories are used by the 
original authors (e.g., categorizing age using a cut point of 5 or 7 years). Fourth, IPDMAs also 
allows one to check model assumption such as linearity or proportional hazard. Lastly by having 
access to individual patient data one can more easily perform subgroup analysis, sensitivity 
analysis and apply more refined methods to deal with problems such as missing values or 
competing risks. However, while we strongly recommend researcher to use IPD techniques in 
meta-analyses one should remember that the success of any meta-analysis ultimately depends 
on quality of the original data. 
 
5. Conclusions 
In conclusion, the IPDMA design used in this study allowed us to assess prognostic factors 
in canines with osteosarcoma. We identified weight, SALP, and tumor location as independent 
prognostic factors of metastasis and mortality, while age was only associated with early 
mortality. This study design allowed for the application of advanced missing data techniques 
and multiple sensitivity analyses and showed the necessity to use individual participant data in 
order to comprehensively assess prognostic factors in this field of research. 
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Table 1 
Characteristics of studies included in the IPDMA for prognostic factors of canine osteosarcoma mortality or metastases3 
 
Table 2 
Baseline characteristics stratified for event status at 5 months and 1 year follow-up for metastases due to osteosarcoma in canines, 
with univariable hazard ratios (HR) and 95% confidence intervals (95%CI). 
 
Table 3 
Multivariable hazard ratios (HR) with 95% confidence intervals (95%CI) and p-values forthe hazard of 




Fig. 1. Kaplan-Meier survival curves for canines with osteosarcoma. Competing risk curve for 
metastases, with biased Kaplan-Meier curve for metastases and mortality without a metastasis. 
Results are based on 511 subjects without missings that had data on both mortality and metastases 
outcome
 

 
